2-氯-4-甲基-3-羟基吡啶 | 884494-70-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 2-氯-4-甲基-3-羟基吡啶
• 中文别名: 2-氯-3-羟基-4-甲基吡啶；2-氯-4-甲基-4-吡啶
• 英文名称: 2-Chlor-3-hydroxy-4-methyl-pyridin
• 英文别名: 2-Chloro-4-methylpyridin-3-ol
• CAS: 884494-70-6
• 化学式: C₆H₆ClNO
• mdl: MFCD04112564
• 分子量: 143.573
• InChiKey: KLEQEGMDNINOTL-UHFFFAOYSA-N

物化性质

• 沸点：
  325.3±37.0 °C(Predicted)
• 密度：
  1.313±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.166
• 拓扑面积：
  33.1
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2933399090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335

文献信息

• [EN] HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS<br/>[FR] COMPOSÉS HÉTÉRO-AROMATIQUES ET LEUR UTILISATION EN TANT QUE LIGANDS D1 DE LA DOPAMINE
  申请人：PFIZER

  公开号：WO2014207601A1

  公开（公告）日：2014-12-31

  The present invention provides, in part, compounds of Formula (I) and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating D1 -mediated (or D1 -associated) disorders including, e.g., schizophrenia (e.g., its cognitive and negative symptoms), cognitive impairment (e.g., cognitive impairment associated with schizophrenia, AD, PD, or pharmacotherapy therapy), age-related cognitive decline, dementia, and Parkinson's disease.

  本发明部分提供了Formula (I)的化合物及其药用盐；其制备方法；制备中使用的中间体；含有这种化合物或盐的组合物，以及它们用于治疗D1介导的（或与D1相关的）疾病，包括但不限于精神分裂症（例如，其认知和消极症状）、认知障碍（例如，与精神分裂症、阿尔茨海默病、帕金森病或药物治疗相关的认知障碍）、年龄相关的认知衰退、痴呆症和帕金森病。
• [EN] MICROBICIDAL HETEROCYCLES<br/>[FR] HÉTÉROCYCLES MICROBICIDES
  申请人：SYNGENTA PARTICIPATIONS AG

  公开号：WO2012069633A1

  公开（公告）日：2012-05-31

  Compounds of the formula I Formula (I) wherein the substituents are as defined in claim 1, are useful as active ingredients, which have microbiocidal activity, in particular fungicidal activity.

  式I的化合物，其中取代基如权利要求1所定义的那样，作为活性成分是有用的，具有微生物杀灭活性，特别是真菌杀灭活性。
• Novel Compounds Derived From 5-Thioxylose And Their Use In Therapeutics
  申请人：Barberousse Veronique

  公开号：US20080293768A1

  公开（公告）日：2008-11-27

  The invention relates to novel 5-thioxylose compounds, preferably derivatives of the 5-thioxylopyranose type, to the process for their preparation and to their use as active principles of drugs intended especially for the treatment or prevention of thrombosis or cardiac insufficiency.

  这项发明涉及新颖的5-硫木糖化合物，优选为5-硫木糖吡喃糖类衍生物，以及它们的制备过程和它们作为药物活性成分的用途，主要用于治疗或预防血栓形成或心脏功能不全。
• Derivatives of 5-Thioxylopyranose and Use of Same for Treatment
  申请人：Barberousse Veronique

  公开号：US20090182013A1

  公开（公告）日：2009-07-16

  The invention relates to new compounds of 5-thioxilose, preferably derivatives of the 5-thioxilopyranose type, and to a method for preparing the same and their use as the active ingredient of drugs mainly intended for treating or inhibiting thrombosis or heart failure or thromboembolic diseases.

  该发明涉及5-硫代木糖的新化合物，优选为5-硫代木糖吡喃糖类的衍生物，以及一种制备这些化合物的方法和它们作为药物活性成分的用途，主要用于治疗或抑制血栓形成、心力衰竭或血栓栓塞性疾病。
• [EN] HETEROCYCLIC COMPOUNDS AS DIHYDROOROTATE DEHYDROGENASE INHIBITORS<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES UTILISÉS EN TANT QU'INHIBITEURS DE LA DIHYDROOROTATE DÉSHYDROGÉNASE
  申请人：JANSSEN BIOTECH INC

  公开号：WO2021156787A1

  公开（公告）日：2021-08-12

  Disclosed are compounds, compositions and methods for treating diseases, disorders, or medical conditions that are affected by the modulation of DHODH. Embodiments of such compounds are represented by Formula (I) and Formula (II) as follows: and wherein R1, R2, R3, R4, R5, R6, R7, R8, X1, X2, X3, X4, Y and Z, are defined herein.

  本文披露了一种通过调节DHODH来治疗受影响的疾病、紊乱或医疗状况的化合物、组合物和方法。这些化合物的实施例由以下的化学式(I)和化学式(II)表示：其中R1、R2、R3、R4、R5、R6、R7、R8、X1、X2、X3、X4、Y和Z在此定义。